Articles

Are you JCA ready? Practical steps for pharma teams

Learn the key steps to JCA readiness. Anticipate PICO scenarios, align evidence with EU HTA, and accelerate market access success.

What the National Cancer Plan for England signals for oncology innovation and access

Explore how the National Cancer Plan for England is reshaping oncology access expectations, regulatory timelines, and HTA and JCA planning.

Why NICE’s new cost-effectiveness threshold matters for pharmaceutical access in the UK

NICE updates its cost-effectiveness threshold. Discover the implications of this change for the UK HTA, patient access, and pricing strategy.

What Is the EU’s pharmaceutical legislation agreement telling the industry?

Overview of the EU pharmaceutical legislation agreement and its implications for the industry, from market exclusivity to regulatory reform.

How strategic market access insights strengthen coverage and accelerate access

Explore how the Acumetis Advisor Network delivers real-world perspectives from payers, PBMs, IDNs, and global access leaders to support stronger market access strategy and decision making.

Direct-to-patient access: Five questions pharma must answer

Direct-to-patient models are reshaping commercialization strategy. Explore key considerations around patient access, operational readiness, scalability, and DTP strategy in this Pharmaphorum interview with Acumetis.

Meet Acumetis at WODC US!

Meet Acumetis at WODC US 2026 in Boston. Connect with our GVA team and explore the evolving challenges of pricing, reimbursement, and patient access for orphan and rare disease therapies.

Generative AI in publications development: Innovation with oversight

Explore how generative AI can enhance medical publication development with the oversight, rigor, and scientific integrity required by Medical Affairs teams.

From approval to patient access: How oncology pharmacy is shaping real-world delivery

Explore how oncology pharmacy services are shaping real-world delivery and patient access, and why operational readiness is critical beyond HTA approval.